LUMIGAN® (bimatoprost ophthalmic solution)
LUMIGAN® 0.03% MD is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers)1
LUMIGAN® (bimatoprost ophthalmic solution 0.01%)
LUMIGAN® (bimatoprost ophthalmic solution 0.03% UD)
What is LUMIGAN® 0.03% MD and how does it work?
LUMIGAN® 0.03% MD belongs to a class drugs known as prostaglandin analogs1
Prostaglandin analogs like LUMIGAN® 0.03% MD work by increasing aqueous humor outflow through the trabecular meshwork and enhancing uveoscleral outflow.1
LUMIGAN® 0.03% MD offers a dual mechanism of action1
The dual mechanism of action stimulates aqueous humour outflow via the trabecular meshwork and uveoscleral pathways, which work together to help lower IOP.1
1 – Increases trabecular meshwork outflow1
2 – Increases uveoscleral outflow1
Image adapted from American Academy of Ophthalmology. 2017.2
Copy from LUMIGAN® 0.03% MD Summary of Product Characteristics. 2022.1
Administration and dosing of LUMIGAN® 0.03% MD
One drop should be administered into the affected eye(s) once daily, in the evening.1
The dose should not exceed once daily, as more frequent administration may lessen the intraocular pressure lowering effect.1
LUMIGAN® 0.03% MD may not be suitable for some of your patients
LUMIGAN® 0.03% MD is contraindicated in:1
Patients with hypersensitivity to the active substance (bimatoprost) or any of the excipients (benzalkonium chloride, sodium chloride, sodium phosphate dibasic heptahydrate, citric acid monohydrate, hydrochloric acid or sodium hydroxide [to adjust pH], and purified water).
Patients who have had a suspected previous adverse reaction to benzalkonium chloride that has led to discontinuation.
Please refer to LUMIGAN® 0.03% MD Summary of Product Characteristics for full safety information and precautions for use.
LUMIGAN® 0.03 mg/mL is indicated for the reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension in adults (as monotherapy or as adjunctive therapy to beta-blockers).1
In clinical studies, over 1800 patients have been treated with LUMIGAN® 0.03 mg/mL eye drops, solution. On combining the data from Phase III monotherapy and adjunctive LUMIGAN® 0.3 mg/mL eye drops, solution usage, the most frequently reported treatment-related adverse events were: growth of eyelashes in up to 45% in the first year with the incidence of new reports decreasing to 7% at 2 years and 2% at 3 years, conjunctival hyperaemia (mostly trace to mild and though to be of a non-inflammatory nature) in up to 44% in the first year with the incidence of new reports decreasing to 13% at 2 years and 12% at 3 years and ocular pruritus in up to 14% of patients in the first year with in the incidence of new reports decreasing to 3% at 2 years and 0% at 3 years. Less than 9% of patients discontinued due to any adverse event in the first year with the incidence of additional patient discontinuations being 3% at both 2 and 3 years.1
Please refer to LUMIGAN® 0.03% MD Summary of Product Characteristics for further information on adverse events.